301201 诚达药业
已收盘 09-04 15:00:00
资讯
新帖
简况
9月4日诚达药业现1笔折价17.99%的大宗交易 合计成交2122.19万元
证券之星 · 09-04 17:27
9月4日诚达药业现1笔折价17.99%的大宗交易 合计成交2122.19万元
破发股诚达药业跌4.82% 上市超募11亿光大证券保荐
中金财经 · 08-28
破发股诚达药业跌4.82% 上市超募11亿光大证券保荐
股市必读：诚达药业新发布《2026年半年度报告摘要》
证券之星 · 08-27
股市必读：诚达药业新发布《2026年半年度报告摘要》
诚达药业扣非连亏2年半 上市超募11亿光大证券保荐
中金财经 · 08-26
诚达药业扣非连亏2年半 上市超募11亿光大证券保荐
诚达药业（301201）披露2026年半年度报告，8月25日股价上涨8.77%
证券之星 · 08-25
诚达药业（301201）披露2026年半年度报告，8月25日股价上涨8.77%
诚达药业(301201)6月30日股东户数1.61万户，较上期增加12.93%
证券之星 · 08-25
诚达药业(301201)6月30日股东户数1.61万户，较上期增加12.93%
诚达药业(301201.SZ)发布上半年业绩，归母净利润229.97万元，同比下降82.07%
智通财经 · 08-25
诚达药业(301201.SZ)发布上半年业绩，归母净利润229.97万元，同比下降82.07%
破发股诚达药业跌7.66% 上市超募11亿光大证券保荐
中金财经 · 08-21
破发股诚达药业跌7.66% 上市超募11亿光大证券保荐
破发股诚达药业跌10.49% 上市超募11亿光大证券保荐
中金财经 · 08-12
破发股诚达药业跌10.49% 上市超募11亿光大证券保荐
诚达药业：2026年一季度扣非净利润较上年同期实现转正
证券之星 · 08-06
诚达药业：2026年一季度扣非净利润较上年同期实现转正
诚达药业（301201）披露补缴税款公告，8月4日股价上涨5.46%
证券之星 · 08-04
诚达药业（301201）披露补缴税款公告，8月4日股价上涨5.46%
7月20日诚达药业跌7.66%，富国睿泽回报混合基金重仓该股
证券之星 · 07-20
7月20日诚达药业跌7.66%，富国睿泽回报混合基金重仓该股
【机构调研记录】华宝基金调研诚达药业、金帝股份
证券之星 · 07-20
【机构调研记录】华宝基金调研诚达药业、金帝股份
股市必读：诚达药业（301201）7月17日披露最新机构调研信息
证券之星 · 07-20
股市必读：诚达药业（301201）7月17日披露最新机构调研信息
诚达药业：招商证券、华宝基金等多家机构于7月17日调研我司
证券之星 · 07-17
诚达药业：招商证券、华宝基金等多家机构于7月17日调研我司
7月17日诚达药业跌12.85%，富国睿泽回报混合基金重仓该股
证券之星 · 07-17
7月17日诚达药业跌12.85%，富国睿泽回报混合基金重仓该股
股市必读：诚达药业（301201）7月15日披露最新机构调研信息
证券之星 · 07-16
股市必读：诚达药业（301201）7月15日披露最新机构调研信息
诚达药业：有知名机构天倚道投资参与的多家机构于7月15日调研我司
证券之星 · 07-15
诚达药业：有知名机构天倚道投资参与的多家机构于7月15日调研我司
7月10日诚达药业涨6.28%，富国睿泽回报混合基金重仓该股
证券之星 · 07-10
7月10日诚达药业涨6.28%，富国睿泽回报混合基金重仓该股
诚达药业（301201）披露2025年度权益分派实施公告，7月9日股价下跌15.63%
证券之星 · 07-09
诚达药业（301201）披露2025年度权益分派实施公告，7月9日股价下跌15.63%
公司概况
公司名称：
诚达药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-20
主营业务：
诚达药业股份有限公司的主营业务是为跨国制药企业及医药研发机构提供关键医药中间体,原料药CDMO研发生产服务，左旋肉碱系列产品,原料药的研发,生产和销售以及干细胞药物的研发。公司的主要产品是利伐沙班、艾拉戈克钠、布立西坦、左卡尼汀、UMC01细胞注射液、(S)-2-(1-溴-8-氨基咪唑并[1,5-a]吡嗪-3-基)吡咯烷-1-羧酸苄酯、4-(2-吡啶基氨甲酰基)苯硼酸、3-硝基-4-[[(四氢-2H-吡喃-4-基)甲基]氨基]苯磺酰胺、1-{[2-（4-氯苯基）-4,4-二甲基-1-环己烯-1-基]甲基}哌嗪二盐酸。
发行价格：
72.69
{"stockData":{"symbol":"301201","market":"SZ","secType":"STK","nameCN":"诚达药业","latestPrice":35.36,"timestamp":1788505380000,"preClose":35.93,"halted":0,"volume":4606882,"delay":0,"changeRate":-0.0159,"floatShares":109000000,"shares":155000000,"eps":-0.1452,"marketStatus":"已收盘","change":-0.57,"latestTime":"09-04 15:00:00","open":36.53,"high":36.97,"low":35.04,"amount":166000000,"amplitude":0.0537,"askPrice":35.37,"askSize":31,"bidPrice":35.36,"bidSize":181,"shortable":0,"etf":0,"ttmEps":-0.1452,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":5,"adr":0,"adjPreClose":35.93,"symbolType":"stock","openAndCloseTimeList":[[1788485400000,1788492600000],[1788498000000,1788505200000]],"highLimit":39.52,"lowLimit":32.34,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":154713824,"isCdr":false,"pbRate":2.65,"roa":"--","roe":"0.11%","epsLYR":-0.0787,"committee":0.452703,"marketValue":5471000000,"turnoverRate":0.0424,"status":1,"floatMarketCap":3838000000},"requestUrl":"/m/hq/s/301201/wiki","defaultTab":"wiki","newsList":[{"id":"2664433879","title":"9月4日诚达药业现1笔折价17.99%的大宗交易 合计成交2122.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664433879","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664433879?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:27","pubTimestamp":1788514073,"startTime":"0","endTime":"0","summary":"证券之星消息，9月4日诚达药业发生大宗交易，交易数据如下：大宗交易成交价格29元，相对当日收盘价折价17.99%，成交73.18万股，成交金额2122.19万元，买方营业部为银泰证券有限责任公司深圳金田路证券营业部，卖方营业部为财通证券股份有限公司深圳后海滨路证券营业部。近三个月该股共发生12笔大宗交易，合计成交7.72万手，折价成交12笔。截至2026年9月4日收盘，诚达药业报收于35.36元，下跌1.59%，换手率4.24%，成交量4.61万手，成交额1.66亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400030403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662050304","title":"破发股诚达药业跌4.82% 上市超募11亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2662050304","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662050304?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:13","pubTimestamp":1787904781,"startTime":"0","endTime":"0","summary":"中国经济网北京8月28日讯 诚达药业 今日收报34.59元，跌幅4.82%。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构为光大证券，保荐代表人为杨科、范国祖。 上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。 诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260828/32351786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601788","BK0012","BK1147","IPOS","BK0183","BK1564","BK0276","BK0188","BK0028","301201","06178","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662592749","title":"股市必读：诚达药业新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662592749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662592749?lang=zh_cn&edition=full","pubTime":"2026-08-27 02:20","pubTimestamp":1787768434,"startTime":"0","endTime":"0","summary":"公司公告汇总：2026年半年度报告摘要显示，公司实现营业收入255,491,382.80元，同比增长40.03%，但归属于上市公司股东的净利润同比下降82.07%至2,299,706.82元。公司公告汇总2026年半年度报告摘要诚达药业股份有限公司发布2026年半年度报告摘要。2026年半年度非经营性资金占用及其他关联资金往来情况汇总表诚达药业股份有限公司披露2026年半年度非经营性资金占用及其他关联资金往来情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700006842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662559764","title":"诚达药业扣非连亏2年半 上市超募11亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2662559764","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662559764?lang=zh_cn&edition=full","pubTime":"2026-08-26 11:36","pubTimestamp":1787715363,"startTime":"0","endTime":"0","summary":"中国经济网北京8月26日讯 诚达药业 昨晚发布2026年半年报，今年上半年，公司营业收入为2.55亿元，同比增长40.03%；归属于上市公司股东的净利润为229.97万元，同比下降82.07%；归属于上市公司股东的扣非净利润为-527.26万元，同比下降281.87%；经营活动产生的现金流量净额为4323.36万元。 诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/26/20260826915548.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/26/20260826915548.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260826/32347704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK0276","BK1147","BK1564","06178","BK0012","BK0188","301201","BK0183","BK0028","BK0239","601788"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662589357","title":"诚达药业（301201）披露2026年半年度报告，8月25日股价上涨8.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662589357","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662589357?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:12","pubTimestamp":1787667179,"startTime":"0","endTime":"0","summary":"近日，诚达药业股份有限公司发布2026年半年度报告摘要。报告期内，公司实现营业收入255,491,382.80元，较上年同期增长40.03%；归属于上市公司股东的净利润为2,299,706.82元，同比下降82.07%；扣除非经常性损益后的净利润为-5,272,563.49元，同比减少281.87%。截至报告期末，公司总资产为2,350,661,974.39元，较上年度末增长0.03%；归属于上市公司股东的净资产为2,096,743,312.24元，较上年度末增长0.11%。公司控股股东及实际控制人在报告期内未发生变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662380707","title":"诚达药业(301201)6月30日股东户数1.61万户，较上期增加12.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662380707","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662380707?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:57","pubTimestamp":1787651844,"startTime":"0","endTime":"0","summary":"证券之星消息，近日诚达药业披露，截至2026年6月30日公司股东户数为1.61万户，较3月31日增加1848.0户，增幅为12.93%。在医疗服务行业个股中，诚达药业股东户数低于行业平均水平，截至6月30日，医疗服务行业平均股东户数为4.77万户。从股价来看，2026年3月31日至2026年6月30日，诚达药业区间跌幅为29.67%，在此期间股东户数增加1848.0户，增幅为12.93%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500037997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662590787","title":"诚达药业(301201.SZ)发布上半年业绩，归母净利润229.97万元，同比下降82.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662590787","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662590787?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:50","pubTimestamp":1787647843,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诚达药业 发布2026年半年度报告，报告期内，公司实现营业收入2.55亿元，同比增长40.03%。实现归属于上市公司股东的净利润229.97万元，同比下降82.07%。归属于上市公司股东的扣除非经常性损益净亏损527.26万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诚达药业(301201.SZ)发布上半年业绩，归母净利润229.97万元，同比下降82.07%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661426683","title":"破发股诚达药业跌7.66% 上市超募11亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2661426683","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661426683?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:54","pubTimestamp":1787302446,"startTime":"0","endTime":"0","summary":"中国经济网北京8月21日讯 诚达药业 今日收报35.80元，跌幅7.66%。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构为光大证券，保荐代表人为杨科、范国祖。 上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。 诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260821/32342833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1564","BK0012","06178","BK0188","BK1147","601788","BK0028","BK0239","IPOS","BK0276","301201","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658876920","title":"破发股诚达药业跌10.49% 上市超募11亿光大证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2658876920","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658876920?lang=zh_cn&edition=full","pubTime":"2026-08-12 16:29","pubTimestamp":1786523347,"startTime":"0","endTime":"0","summary":"中国经济网北京8月12日讯 诚达药业 今日收报35.75元，跌幅10.49%。 诚达药业于2022年1月20日在深交所创业板上市，公开发行新股2,417.4035万股，发行价格为72.69元/股，保荐机构为光大证券，保荐代表人为杨科、范国祖。 上市首日，诚达药业盘中最高报188.00元，为该股上市以来最高点。 诚达药业首次公开发行股票发行费用总额为13,576.31万元，其中，保荐承销费用11,792.90万元。 诚达药业于2023年7月3日披露分红方案，每10股转增6股，派息(税前)3元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260812/32332800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","301201","BK1564","BK1147","06178","601788","BK0183","BK0239","IPOS","BK0188","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657683969","title":"诚达药业：2026年一季度扣非净利润较上年同期实现转正","url":"https://stock-news.laohu8.com/highlight/detail?id=2657683969","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657683969?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:36","pubTimestamp":1786001768,"startTime":"0","endTime":"0","summary":"证券之星消息，诚达药业08月06日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600020796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656578395","title":"诚达药业（301201）披露补缴税款公告，8月4日股价上涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656578395","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656578395?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:45","pubTimestamp":1785854717,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘，诚达药业报收于29.75元，较前一交易日上涨5.46%，最新总市值为46.03亿元。该股当日开盘28.77元，最高29.8元，最低28.5元，成交额达1.85亿元，换手率为5.86%。公司于近日披露《关于补缴税款的公告》。公告显示，诚达药业股份有限公司根据税务监管要求开展自查，需补缴企业所得税、房产税、增值税、附加税及滞纳金合计163.77万元。截至公告披露日，上述款项已全部缴纳完毕，不涉及行政处罚。本次补缴不影响公司正常经营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652993832","title":"7月20日诚达药业跌7.66%，富国睿泽回报混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652993832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652993832?lang=zh_cn&edition=full","pubTime":"2026-07-20 16:52","pubTimestamp":1784537561,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日诚达药业跌7.66%创60日新低，收盘报30.74元，换手率9.62%，成交量10.44万手，成交额3.36亿元。重仓诚达药业的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为富国基金的富国睿泽回报混合。富国睿泽回报混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000025262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652833263","title":"【机构调研记录】华宝基金调研诚达药业、金帝股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652833263","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652833263?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:01","pubTimestamp":1784505694,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及7月17日披露的机构调研信息，华宝基金近期对2家上市公司进行了调研，相关名单如下：1）诚达药业 调研纪要：公司左旋肉碱系列产品价格稳定，出口全球30多个国家，已获中国NMPA、美国FDA、日本PMDA、欧洲CEP等多国认证，Self-GRAS认证已完成。2）金帝股份 调研纪要：2025年公司实现营业收入20.20亿元，同比增长49.07%，净利润1.47亿元，同比增长47.86%；2026年一季度营收5.27亿元，同比增长38.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000001846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603270","301201","BK0259","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652252143","title":"股市必读：诚达药业（301201）7月17日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2652252143","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652252143?lang=zh_cn&edition=full","pubTime":"2026-07-20 01:03","pubTimestamp":1784480590,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，诚达药业报收于33.29元，下跌12.85%，换手率11.13%，成交量12.09万手，成交额4.25亿元。当日关注点交易信息汇总：7月17日主力资金净流出2473.68万元，散户资金净流入3022.9万元。机构调研要点：公司反应设备总容积达141.55万升，具备多功能柔性化生产线及多次欧美客户质量审计通过记录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000000509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652074794","title":"诚达药业：招商证券、华宝基金等多家机构于7月17日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2652074794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652074794?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:01","pubTimestamp":1784286068,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月17日诚达药业发布公告称招商证券方秋实、华宝基金魏扬帆于2026年7月17日调研我司。诚达药业2026年一季报显示，一季度公司主营收入1.28亿元，同比上升68.06%；归母净利润700.2万元，同比上升600.15%；扣非净利润309.86万元，同比上升152.93%；负债率9.78%，投资收益3.08万元，财务费用192.6万元，毛利率33.13%。该股最近90天内共有1家机构给出评级，增持评级1家。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700037039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0276","301201","BK1564","BK1147","06099","BK0010","BK0239","BK0183","BK0188","600999","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652040955","title":"7月17日诚达药业跌12.85%，富国睿泽回报混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652040955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652040955?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:59","pubTimestamp":1784278790,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日诚达药业跌12.85%，收盘报33.29元，换手率11.13%，成交量12.09万手，成交额4.25亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为富国基金的富国睿泽回报混合。富国睿泽回报混合目前规模为2.58亿元，最新净值1.8799，较上一交易日下跌1.83%，近一年上涨13.88%。富国睿泽回报混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651101460","title":"股市必读：诚达药业（301201）7月15日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2651101460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651101460?lang=zh_cn&edition=full","pubTime":"2026-07-16 01:39","pubTimestamp":1784137149,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，诚达药业报收于37.94元，上涨2.26%，换手率13.04%，成交量14.15万手，成交额5.43亿元。当日关注点交易信息汇总：7月15日主力资金净流出998.87万元。机构调研要点7月15日特定对象调研公司目前开展的小分子GLP-1药物中间体有多个片段，将结合市场需求及客户需要拓展更多种类。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071600001817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465470","title":"诚达药业：有知名机构天倚道投资参与的多家机构于7月15日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465470","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651465470?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:02","pubTimestamp":1784120524,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年7月15日诚达药业发布公告称天倚道投资郝俊辉于2026年7月15日调研我司。诚达药业2026年一季报显示，一季度公司主营收入1.28亿元，同比上升68.06%；归母净利润700.2万元，同比上升600.15%；扣非净利润309.86万元，同比上升152.93%；负债率9.78%，投资收益3.08万元，财务费用192.6万元，毛利率33.13%。该股最近90天内共有1家机构给出评级，增持评级1家。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500043242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183060","title":"7月10日诚达药业涨6.28%，富国睿泽回报混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650183060?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:37","pubTimestamp":1783672632,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日诚达药业涨6.28%，收盘报36.88元，换手率16.76%，成交量18.19万手，成交额6.65亿元。重仓诚达药业的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为富国基金的富国睿泽回报混合。富国睿泽回报混合的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650940926","title":"诚达药业（301201）披露2025年度权益分派实施公告，7月9日股价下跌15.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650940926","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650940926?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:17","pubTimestamp":1783588677,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘，诚达药业报收于34.7元，较前一交易日下跌15.63%，最新总市值为53.69亿元。该股当日开盘39.4元，最高40.81元，最低33.34元，成交额达9.01亿元，换手率为22.53%。公司于近日披露《2025年度权益分派实施公告》。本次权益分派实施后，相关股东减持价及除权除息参考价将作相应调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900030239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301201"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788652380819,"stockEarnings":[{"period":"1week","weight":0.0223},{"period":"1month","weight":0.1341},{"period":"3month","weight":0.0104},{"period":"6month","weight":-0.1685},{"period":"1year","weight":0.2459},{"period":"ytd","weight":-0.1266}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":0.0133},{"period":"3month","weight":-0.0242},{"period":"6month","weight":-0.0471},{"period":"1year","weight":0.0436},{"period":"ytd","weight":-0.0098}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"诚达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"16143人(较上一季度增加12.93%)","perCapita":"6723股","listingDate":"2022-01-20","address":"浙江省嘉兴市嘉善县惠民街道黄河路36号","registeredCapital":"15471万元","survey":" 诚达药业股份有限公司的主营业务是为跨国制药企业及医药研发机构提供关键医药中间体,原料药CDMO研发生产服务，左旋肉碱系列产品,原料药的研发,生产和销售以及干细胞药物的研发。公司的主要产品是利伐沙班、艾拉戈克钠、布立西坦、左卡尼汀、UMC01细胞注射液、(S)-2-(1-溴-8-氨基咪唑并[1,5-a]吡嗪-3-基)吡咯烷-1-羧酸苄酯、4-(2-吡啶基氨甲酰基)苯硼酸、3-硝基-4-[[(四氢-2H-吡喃-4-基)甲基]氨基]苯磺酰胺、1-{[2-（4-氯苯基）-4,4-二甲基-1-环己烯-1-基]甲基}哌嗪二盐酸。","listedPrice":72.69},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诚达药业,301201,诚达药业股票,诚达药业股票老虎,诚达药业股票老虎国际,诚达药业行情,诚达药业股票行情,诚达药业股价,诚达药业股市,诚达药业股票价格,诚达药业股票交易,诚达药业股票购买,诚达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诚达药业(301201)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诚达药业(301201)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}